be produced via the backdoor pathways. 5, 8, 9 Several pharmacological inhibitors of androgen-metabolizing enzymes have been employed in attempts to prevent intracrine production of T and DHT in CRPC patients, and the clinical success of these strategies has been mixed. Abiraterone, a cytochrome P450 17A1 (CYP17A1) inhibitor, decreased serum concentrations of DHEA, ASD, and T 10 and extended median overall survival by 3.9 months.
11
Resistance of CRPC to abiraterone and other CYP17A1 inhibitors was attributed to a number of potential mechanisms that included AR splice variants and increased intratumoral expression of CYP17A1 observed in conjunction with CYP17A1 inhibition. 12, 13 Dutasteride, a SRD5A
inhibitor, decreased serum DHT concentrations 14 ; however, dutasteride was ineffective against CRPC in a phase II clinical trial. 15 Potential explanations for this clinical failure of dutasteride included accumulation of T, which activates AR but to a lesser extent than DHT, and aromatization of T to estrogen, which may activate mutant AR. 16 Aldo-keto reductase 1C3 (AKR1C3) inhibitors reduced CRPC growth in vitro 17 and in xenograft models, 12,18 but a phase I/II trial of an AKR1C3-specific inhibitor in subjects with metastatic CRPC was terminated early due to a lack of clinical efficacy. 19 The general strategy of blocking intracrine androgen biosynthesis still represents a promising option for CRPC therapy. 20, 21 Mathematical modeling provides a valuable tool for application to studies of androgen metabolism in CRPC because it can be used to integrate existing knowledge and to detect and define gaps in understanding. association rate constant (k on ) and a first-order dissociation rate constant (k off ), and an irreversible catalysis step, parameterized with a first-order rate constant (k cat ). The rates of change for each component were described using ordinary differential equations, which were solved using the ode15s solver. This solver uses a variable order, multistep integration method that is based on the numerical differentiation formulas and is suited for solving stiff differential equations. 23 The change in amount of substrate over time was described according to Equation 1:
complexÞ
Àk on3 Â AND Â DHRS þ k off3 Â ðDHRS9 -AND complexÞ
Representative examples included the change in amount of enzyme over time and the change in amount of enzyme-substrate complex over time, which were shown for HSD17B6 in Equations 2 and 3, respectively: All association rate constants (k on1-4 ) were approximated as 10 000 µM −1 · s −1 based on diffusion rate limits and the approximate radii of enzyme (25 Å) and substrate (5 Å). 24 Catalysis was assumed to be the rate-limiting step in each enzymatic reaction; k off was assumed to be 100-fold greater than k cat . Absolute values for k off and k cat were calculated using Equation 5 24 : Media concentrations of AND and 5α-dione were determined as reported 28 using a previously described LC-MS/MS method. 31 Study samples were quantitated using aqueous-based spiked calibration standards and pre-spiked quality control samples prepared in 2X 
FIGURE 2
Mathematical model for conversion of androsterone (AND) to androstanedione (5α-dione) via 3α-oxidoreductase enzymes. The model included components for substrate (AND), product (5α-dione), each of the four 3α-oxidoreductase enzymes (HSD17B6, RDH16, DHRS9, and RDH5), and each of the four enzyme-substrate complexes. Each enzymatic reaction consisted of a reversible enzyme-substrate binding step, which was parameterized in terms of a second-order association rate constant (k on ) and a first-order dissociation rate constant (k off ), and an irreversible catalysis step, which was parameterized with a first-order rate constant (k cat ) HSD17B6 based on protein sequence similarity of the catalytic amino acid residues that shared 100% identity. 28 Relative enzyme amounts from gene expression data were shown in FIGURE 3 3α-oxidoreductase gene expression in CV-1 and LAPC-4 cells was measured using qRT-PCR. Data were presented as mean ± standard error of the mean for three technical replicates and three biological replicates. Mean values were provided in text above each bar. DHRS9 expression levels in three LAPC-4 samples (one from one biological replicate and two from another) were lower than the limit of detection (>38-40 cycles) and were treated as zero in summary statistics calculations. Note that the y-axis scales in the two panels differed by 10-fold A literature K M value for the oxidation of androsterone to androstanedione by RDH5 was unavailable, so K M was assumed to be the same as that for HSD17B6 based on protein sequence similarity at the active site.
COOK ET AL.
| 1073 process of androgen metabolism but also should support the description of longer-term biological changes, such as inhibition or induction of enzyme expression.
The work presented herein represents a first step toward a comprehensive androgen metabolism model. The approach has adhered to these criteria so that additional biological complexity can be incorporated efficiently in future efforts. Two model features critical to meet these criteria were the explicit description of the enzymatic species and the division of the substrate-product conversion into a reversible enzyme-substrate binding step and an irreversible catalysis step. A simpler approach, employed in mathematical models of other metabolic processes, [32] [33] [34] describes the direct conversion of substrate to product at a rate dictated by MichaelisMenten kinetics (Equation 6):
where v is the reaction rate, S is the substrate concentration, V max is the maximum reaction rate that occurs at saturating substrate concentrations and K M is the Michaelis-Menten constant, which is equivalent to the substrate concentration at which the reaction rate reaches half of V max . Equation 6 does not specify the amount of enzyme; instead, the enzyme amount is incorporated indirectly via
where k cat is the catalytic rate constant and E 0 is the initial enzyme concentration. 24 The Michaelis-Menten approach has several limitations. First, V max depends upon enzyme concentration, so The four 3α-oxidoreductases were not detectable using western blotting, so gene expression data were used to establish relative enzyme amounts. Relative gene expression was assumed to correlate with relative enzyme activity, but this assumption often does not hold true. Nevertheless, enzyme concentrations that were estimated from the CV-1 cell line were extrapolated to the LAPC-4 cell line with reasonable accuracy using gene expression data, and this finding suggested that the aforementioned approach was reasonable. Expansion of this framework to a more comprehensive model of androgen metabolism will require careful testing for sensitivity to these assumptions. In particular, the assumption regarding the relationship between gene expression and enzyme activity may be less plausible in more complex scenarios where the gene expression distributions are not skewed so markedly toward a single enzyme, and it may be necessary to obtain additional experimental data in such cases.
| CONCLUSIONS
We used an in silico mathematical modeling approach to model the oxidation of AND to 5α-dione by four 3α-oxidoreductase enzymes in two different cell lines, a non-CaP cell line (CV-1) and a CaP cell line (LAPC-4). All parameter values were derived either from literature sources or from existing experimental data. A systematic approach was used to develop the mathematical model, and the model reproduced the in vitro experimental observations. This work was the first step toward development of a comprehensive mathematical model of androgen metabolism for application to studies of CRPC. The methodology provides an adaptable, extensible, and mechanistic framework that can be expanded to include models with additional complexity. Future efforts will focus on incorporation of additional biochemical reactions and manipulation of metabolic pathways so that, ultimately, the model will facilitate identification of promising therapeutic targets and approaches for CRPC treatment.
